Lincoln Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lincoln Pharmaceuticals reported standalone and consolidated audited financial results for FY2025-26. Total income grew 9.10% to Rs 704.48 crore from Rs 645.71 crore in the prior year. Net profit increased 6.74% to Rs 87.89 crore from Rs 82.35 crore. EBITDA rose 5.78% to Rs 131.14 crore. EPS improved to Rs 43.88 from Rs 41.11. The Board recommended a dividend of 18% (Rs 1.80 per share). The statutory auditors issued an un-modified (clean) audit opinion. FII holding increased from 5.00% to 5.20% as of March 31, 2026. The company targets Rs 1,000 crore revenue in 3 years with 15-18% annual growth driven by cardiac, diabetic, dermatology and ENT segments.
Positive results with consistent growth across revenue, profit and EBITDA. Clean audit opinion and dividend recommendation indicate financial stability. However, growth rates are moderate (6-9%) rather than high growth, which may limit immediate stock price upside.